Case Reports in Oncology最新文献

{"title":"MRI-Guided Adaptive Radiation Therapy for Oligometastatic Prostate Cancer Involving the Adrenal Gland: A Case Report and Literature Review.","authors":"Fabian J Bolte, Christopher K Luminais, Matthew Mistro, Michael E Devitt","doi":"10.1159/000545983","DOIUrl":"10.1159/000545983","url":null,"abstract":"<p><strong>Introduction: </strong>Metastasis-directed therapy is an evolving treatment modality for patients with oligometastatic prostate cancer. Although the microenvironment of the adrenal glands is enriched in androgen precursors, isolated adrenal metastases are rare. The application of stereotactic ablative radiotherapy (SBRT) to oligometastatic adrenal lesions has been limited due to toxicity concerns.</p><p><strong>Case presentation: </strong>We report a patient with castration resistant prostate cancer and oligometastatic disease recurrence to the adrenal gland who underwent MRI-guided adaptive radiotherapy, which allowed accurate delivery of SBRT while minimizing exposure to adjacent radiosensitive organs. This approach was safe and resulted in long-term local and systemic disease control.</p><p><strong>Conclusion: </strong>This case highlights the potential role for MRI-guided SBRT in selected patients with oligometastatic prostate cancer to the adrenal glands.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"638-645"},"PeriodicalIF":0.7,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"38-Year Delayed Spinal Leptomeningeal Dissemination of a Paediatric Pilocytic Astrocytoma: A Case Report.","authors":"Alexander Irving, Simon Lammy, Likhith Alakandy","doi":"10.1159/000545935","DOIUrl":"10.1159/000545935","url":null,"abstract":"<p><strong>Introduction: </strong>Pilocytic astrocytoma (PA) is among the commonest primary intracranial tumours in children but has a low incidence among the adult population, and spinal occurrences are particularly infrequent. We report a spinal intradural extramedullary (IDEM) recurrence of this tumour a significant duration after initial treatment. Such a case is previously unreported in the literature.</p><p><strong>Case summary: </strong>A 46-year-old female presented with a 3-month history of worsening back pain. Reduced sensation on the right side in L1, L2, and per rectum was found on examination. MRI displayed a L3 IDEM mass. Background was significant for childhood PA, debulked at age 8 and 13. Right L3 hemilaminectomy and subtotal resection was performed. The mass was found to be composed of pleomorphic astroglial cells and was glial fibrillary acidic protein-positive with a fusion between exon 16 of KIAA1549 and exon 9 of BRAF. A recurrence of pilocytic astrocytoma in the lumbar spine was diagnosed, over 38 years after previous treatment.</p><p><strong>Conclusion: </strong>This novel case of long-term leptomeningeal dissemination of cerebellar PA to the lumbar spine is unprecedented. The delayed dissemination of this tumour may warrant further molecular investigation of pilocytic astrocytoma to assess underlying predispositions for such a presentation.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"702-710"},"PeriodicalIF":0.7,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis.","authors":"Nadav Weijel, Safwat Odeh, Amjad Mousa, Nina Nazarov, Olga Zelman, Ilana Levy Yurkovski","doi":"10.1159/000545677","DOIUrl":"10.1159/000545677","url":null,"abstract":"<p><strong>Introduction: </strong>Obinutuzumab, an anti-CD20 antibody, is widely used in the treatment of B-cell lymphomas. While diarrhea is a known side effect, obinutuzumab-induced inflammatory bowel disease (IBD)-like conditions are rarely reported. Here, we present a case of obinutuzumab-induced pancolitis.</p><p><strong>Case presentation: </strong>A 69-year-old male with stage IV follicular lymphoma, treated with obinutuzumab-CHOP and subsequent obinutuzumab maintenance therapy, developed non-bloody diarrhea after his third maintenance dose. Endoscopic and histological findings mimicked Crohn's disease, leading to a diagnosis of obinutuzumab-induced pancolitis. Obinutuzumab was discontinued, and the patient was transitioned to infliximab therapy, leading to partial improvement.</p><p><strong>Conclusion: </strong>This case demonstrates a severe instance of obinutuzumab-induced pancolitis with IBD-like features, emphasizing the need for clinicians to consider drug-induced etiologies in patients presenting with new gastrointestinal symptoms during obinutuzumab therapy. Timely diagnosis and a multidisciplinary approach are crucial for effective management. Further reports are needed to better understand the full spectrum of gastrointestinal toxicity associated with obinutuzumab and guide future treatment.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"613-619"},"PeriodicalIF":0.7,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Signet Ring Cell Carcinoma of the Stomach with Chylous Pleural Effusion: Laterality Shift and Fluid Composition Change.","authors":"Akina Nigi, Toshikazu Kumasa, Keisuke Iwamoto, Junichiro Nishiki, Haruka Nakamura, Hidetoshi Itani, Shigeto Kondou","doi":"10.1159/000545958","DOIUrl":"10.1159/000545958","url":null,"abstract":"<p><strong>Introduction: </strong>Chylothorax is a rare manifestation of malignant pleural effusion, with gastric cancer accounting for only a small percentage of cases. Signet ring cell carcinoma (SRCC) is an aggressive tumor subtype that frequently invades the lymphatic system, leading to early dissemination.</p><p><strong>Case presentation: </strong>A 66-year-old woman presented with bilateral chylothorax that was initially suspected to be a lymphoma. After a transient resolution, the pleural effusion returned on the left side, with a shift from chylous to non-chylous fluid and an increase in carcinoembryonic antigen levels. Despite endoscopic findings resembling early stage gastric cancer, cytology confirmed SRCC. Despite treatment with capecitabine plus oxaliplatin and nivolumab, the disease progressed, resulting in bilateral effusion recurrence and death within 4 months. Genetic analysis revealed CLDN18.2 positivity.</p><p><strong>Conclusion: </strong>This case is unique because it demonstrates a rare progression from bilateral to unilateral pleural effusion, accompanied by a transition in pleural fluid characteristics, which has not been previously reported. The observations suggest dynamic changes in lymphatic obstruction and tumor infiltration. Early molecular profiling, which includes CLDN18.2 testing, may provide new opportunities for targeted therapy in aggressive gastric cancer cases.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"694-701"},"PeriodicalIF":0.7,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intramedullary Glioblastoma as One of Multiple Radiation-Induced Neoplasms.","authors":"Kacper Koczyk, Arkadiusz Nowak, Marcin M Machnicki, Łukasz Zdzisław Michałowski, Edyta Maj, Tomasz Stoklosa, Przemysław Kunert","doi":"10.1159/000545250","DOIUrl":"10.1159/000545250","url":null,"abstract":"<p><strong>Introduction: </strong>Intramedullary glioblastoma is a rare entity comprising 1.4-9% of spinal gliomas. Spinal cord radiation-induced gliomas are unique, with only 13 cases reported to date.</p><p><strong>Case presentation: </strong>A 53-year-old female with a history of mediastinal Hodgkin lymphoma treated with chemotherapy and radiotherapy who subsequently developed thyroid cancer and breast cancer throughout her life was admitted due to slowly progressing spastic tetraparesis. Cervical MRI revealed an intramedullary lesion at the C4-T1 level, enlarging the spinal cord, with a heterogenous contrast enhancement and a lesion within T1 vertebral body showing contrast enhancement. Whole-body ¹⁸F-FDG-PET/CT revealed increased radionuclide uptake within the cervical spinal cord at the C2-C7 level and a focus of increased metabolic activity within the T1 vertebral body. The patient underwent a C4-T2 laminectomy with tumor debulking, and a biopsy of the T1 vertebral body was taken. Closure was performed with thecal sac expansion using a fascia lata graft and open-door laminoplasty. The histomolecular results confirmed the diagnosis of glioblastoma, IDH-wildtype (CNS WHO G4), in the cervical spinal cord lesion and breast cancer metastasis in the T1 vertebral body. Postoperatively, the patient experienced progression of lower extremities and left arm paresis. No adjuvant therapy was administered due to neurological deficit progression. The patient died 6 months after surgery.</p><p><strong>Conclusion: </strong>We report a case of an intramedullary glioblastoma in a patient with a history of radiation and multiple neoplasms located at the irradiation field borders. The full molecular analysis allowed for classification of the tumor as glioblastoma, IDH-wildtype (CNS WHO G4), and screening for germinal mutations potentially predisposing to spontaneous neoplasm development.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"682-693"},"PeriodicalIF":0.7,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cushing's Syndrome due to a Renal Neuroendocrine Tumor: A Case Report.","authors":"Vicka Poudyal, Marianne S Elston, Saleen Nottingham, Michael J Swarbrick, Adam Davies, Veronica Boyle","doi":"10.1159/000545734","DOIUrl":"10.1159/000545734","url":null,"abstract":"<p><strong>Introduction: </strong>Cushing's syndrome (CS) due to ectopic adrenocorticotrophic hormone (ACTH) is rare and usually due to neuroendocrine neoplasia (NEN). Primary renal NEN is exceptionally rare but may be a cause of rapidly progressive CS.</p><p><strong>Case presentation: </strong>A 51-year-old man presented with profound hypokalemia, cellulitis, and new-onset type 2 diabetes and hypertension with 1 month of muscle weakness, labile mood, and insomnia. CS due to ectopic ACTH production was confirmed. Biochemical control was achieved using a \"block-and-replace\" regimen with dual blockade with ketoconazole and metyrapone and hydrocortisone replacement in addition to mineralocorticoid receptor blockade using spironolactone. CT and ultrasound demonstrated a 24 mm right renal lesion with features concerning for renal cell carcinoma. Right laparoscopic nephrectomy was performed. Histology demonstrated a WHO grade one NEN with ACTH staining.</p><p><strong>Conclusion: </strong>In CS, where the source of ectopic ACTH production is unable to be identified, a renal source should be considered. Diagnosis may be difficult as there are no reliable radiological characteristics to distinguish renal NENs from renal cell carcinomas, so a high degree of suspicion is required.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"593-601"},"PeriodicalIF":0.7,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Immune-Related Adverse Events, Including Myasthenia Gravis, Myositis, and Myocarditis, during Avelumab and Axitinib Combination Therapy.","authors":"Jurii Karibe, Ryohei Horiguchi, Yohei Hanajima, Akihito Hashizume, Daiji Takamoto, Takashi Kawahara, Kimito Osaka, Jun-Ichi Teranishi, Naohisa Ueda, Hiroji Uemura","doi":"10.1159/000545733","DOIUrl":"https://doi.org/10.1159/000545733","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint inhibitors are the mainstay of treatment for unresectable or metastatic renal cell carcinoma (RCC). However, they can cause immune-related adverse events (irAEs), and the management of these irAEs is critical. The combination of myasthenia gravis, myositis, and myocarditis, which are irAEs, is rare, and it has not been reported to occur with avelumab. This report aimed to present a rare case of RCC metastasis that developed irAEs during avelumab and axitinib combination therapy.</p><p><strong>Case presentation: </strong>A 76-year-old woman who underwent radical nephrectomy for clear cell RCC (pT1bN0M0 Grade 3 INFb) at the age of 67 years presented to our hospital after her family doctor noted a pancreatic tumor. She was diagnosed with pancreatic metastasis of RCC based on histopathological examination, and avelumab and axitinib combination therapy was initiated. She developed irAEs, including myasthenia gravis, myositis, and myocarditis, which were treated with steroid pulse therapy. The patient recovered after treatment and was discharged without sequelae.</p><p><strong>Conclusion: </strong>Myasthenia gravis, myositis, and myocarditis can occur during avelumab and axitinib combination therapy for RCC. Prompt diagnosis, treatment, and collaboration with other departments are extremely important for managing irAEs.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"563-569"},"PeriodicalIF":0.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review.","authors":"Taiki Ishida, Ken Morita, Yosuke Masamoto, Hideaki Mizuno, Kazuki Taoka, Hiroyuki Abe, Motoki Odawara, Yosuke Hirakawa, Masaomi Nangaku, Mineo Kurokawa","doi":"10.1159/000545498","DOIUrl":"https://doi.org/10.1159/000545498","url":null,"abstract":"<p><strong>Introduction: </strong>Fibrillary glomerulonephritis (FGN) is a rare form of immune complex-mediated primary glomerular disease frequently coexisting with malignancies or autoimmune diseases. The kidney prognosis is extremely poor, with approximately 50% of patients progressing to end-stage kidney disease within 2-4 years after diagnosis. However, no established treatment currently exists.</p><p><strong>Case presentation: </strong>Here we describe a rare case of FGN diagnosed in a patient progressing from monoclonal gammopathy to multiple myeloma. The histopathological findings of the kidney biopsy were consistent with classical FGN and revealed no evidence of myeloma cast nephropathy. Albumin-dominant, Bence Jones protein-negative proteinuria further supported this diagnosis. The patient was successfully treated with anti-myeloma chemotherapies including autologous stem cell transplant, resulting in significant improvement in kidney function.</p><p><strong>Conclusion: </strong>Based on our experience, secondary FGN associated with plasma cell neoplasms may represent a rare entity that responds favorably to anti-myeloma therapies. Initial investigations to rule out coexistent plasma cell neoplasms are crucial for the optimal management of FGN patients.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"554-562"},"PeriodicalIF":0.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report.","authors":"Jeremy Rosiecki, Natalie Wallace, Katelyn Kammers, Ann-Chee Cheng, Talia Wyckoff, Steven Liu","doi":"10.1159/000545372","DOIUrl":"10.1159/000545372","url":null,"abstract":"<p><strong>Introduction: </strong>Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) poses considerable treatment challenges, with disheartening odds of long-term survival. Numerous strategies exist, including non-cross-resistant combination chemoimmunotherapy regimens, autologous stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy, but some patients are not appropriate candidates or cannot sustain response to treatment. Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, has been given accelerated approval by the US Food and Drug Administration for relapsed or refractory DLBCL.</p><p><strong>Case presentation: </strong>We present the case of a 61-year-old male diagnosed with stage 4 \"double-hit\" DLBCL with <i>MYC</i> and <i>BCL6</i> rearrangement, who initially received one cycle of rituximab HyperCVAD (initiated July 23, 2021). He then received dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) followed by high-dose methotrexate and initially responded but relapsed several months later. As the patient was not a candidate for transplant, subsequent treatment rounds included rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) and CD19 CAR T-cell therapy; tafasitamab-cxix and lenalidomide; and polatuzumab vedotin plus bendamustine and rituximab (pola-BR). Despite intermittent treatment response, his disease continued to progress. He began treatment with epcoritamab through the early access program but showed early signs of continued progression; his status deteriorated until further treatment had to be withheld. Within approximately 1 month, he could resume treatment, achieving a Deauville score of 1 approximately 3 months after beginning epcoritamab, and continues follow-up nearly 2 years later.</p><p><strong>Conclusion: </strong>T-cell engager therapies, such as epcoritamab, can play a role in managing patients with refractory DLBCL, including those refractory to CAR T-cell therapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"744-750"},"PeriodicalIF":0.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excellent Response to Trastuzumab Deruxtecan of a Large Medullary Metastasis from Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Case Report.","authors":"Aoi Kuroda, Mao Uematsu, Mai Shimura, Akira Hirota, Misao Fukuda, Nobuyuki Takahashi, Hiromichi Nakajima, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Yoichi Naito, Toru Mukohara","doi":"10.1159/000545577","DOIUrl":"https://doi.org/10.1159/000545577","url":null,"abstract":"<p><strong>Introduction: </strong>Brain metastasis is a serious complication in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Brainstem metastases are particularly challenging to treat because of the high risks associated with surgery and stereotactic radiosurgery (SRS).</p><p><strong>Case presentation: </strong>We present a case of a 56-year-old woman with HER2-positive breast cancer who developed multiple brain metastases, including a large medullary lesion, 9 months after surgery confirming a pathological complete response to standard trastuzumab plus pertuzumab-based neoadjuvant chemotherapy, without extracranial lesions. Surgery was deemed infeasible because the lesion's location and size posed high risks of toxicity from SRS. Promising intracranial responses to trastuzumab deruxtecan (T-DXd) have been reported; therefore, T-DXd was chosen. Remarkable symptomatic improvements were observed within days after initiating T-DXd. Imaging confirmed radiographic responses and metabolic response indicated by the absence of uptake of ¹¹C-methionine on positron emission tomography-computed tomography. No evidence of relapse has been observed after the 14 months since the initiation of T-DXd.</p><p><strong>Conclusion: </strong>This case indicates the efficacy of T-DXd in treating large medullary metastases, achieving rapid and sustained responses even in high-risk situations where conventional therapies may not be suitable. Furthermore, the fact that the brain metastases occurred after pathological complete response without extracranial lesions may indicate the superiority of T-DXd over conventional anti-HER2 antibodies for brain metastasis. This case underscores the potential of T-DXd as a viable treatment option for brain metastases. Further studies are required to establish its safety and efficacy in similar high-risk scenarios.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"523-530"},"PeriodicalIF":0.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}